Semaglutide Raw Powder

Semaglutide yog qhov ntev - ua GLP-1 analog engineered nrog Lys26 C18-diacid acylation ntawm -Glu-(AEEA)₂ linker thiab Aib hloov pauv los txhim kho DPP-4 stability thiab albumin binding. Medibridge Biotech (Tuam Tshoj) khiav cov kab SPPS automated nrog nruj hauv - cov txheej txheem tswj thiab ntau ntau- tso tawm kev sim (RP-HPLC purity, LC-MS tus kheej, cov ntsiab lus peptide, endotoxin). Muab cov peptide ntau thiab vialed configurations, peb ua hauj lwm thoob ntiaj teb labs raws li ib tug semaglutide chaw tsim tshuaj paus thiab semaglutide tsum, xa high-purity semaglutide nrog batch traceability, kev cai vial ntau thiab tsawg / daim ntawv lo, thiab txhim khu kev qha txias-chain logistics. Vim li ntawd,semaglutide nyoos hmoovtxhawb nqa txoj kev txhim kho zoo ib yam, siv - qauv kev npaj, thiab kev tshuaj ntsuam xyuas hauv cov txheej txheem metabolic- tshawb fawb workflows.

Ntau dua los yog sib npaug rau 99.81% purity, RP-HPLC txheeb xyuas

Batch COA & thib peb -tso rov qab xeem txaus txaus

Orders shipping sai li 24 teev

Kev cai vial loj, cap xim & labeling muaj

Kev xa khoom thoob ntiaj teb nrog rau kev ncaj ncees / UPS / DHL / FedEx thiab lwm yam.

Cov ntaub ntawv tshawb fawb piav qhia txog cov piam thaj hauv lub cev muaj zog- txo qis thiab muaj txiaj ntsig zoo hauv lub cev- qhov hnyav txo nrog GLP-1 receptor agonism, muaj kev pheej hmoo tsawg ntawm cov piam thaj hauv cov ntshav thaum tsis ua ke nrog cov tshuaj insulin secretagogues, thiab feem ntau ua rau lub plab zom mov ua kom zoo dua nrog kev siv tshuaj maj mam. Hauv qhov hnyav- kev tswj hwm, kev saib xyuas mus sij hawm ntev nrog rau kev ntsuas kev ua neej feem ntau yog tham txog kev txhawb nqa cov txiaj ntsig thiab txo qhov hnyav dua.

Pom zoo diluents & Tshuag

Thawj: dej tsis muaj menyuam lossis PBS (pH 7.2–7.4).

Rau kev ntub dej nyuaj: ua ntej- ntub nrog 10–30 µL DMSO lossis 0.1–1% acetic acid, tom qab ntawd nqa mus rau ntim nrog tsis muaj.

Kev tshawb fawb cov khoom lag luam: 0.5-2.0 mg / mL (ua kom zoo rau ib qho kev ntsuam xyuas; ntau dua tuaj yeem ua kom sib sau ua ke).

Kev tawg

Maj mam swirl / qaij; tsis txhob muaj zog vortexing los yog foaming.

Kev daws yuav tsum yog qhov tseeb; Yog hais tias turbidity tseem, kho pH mus rau nruab nrab thiab / los yog ntxiv Tsawg dua los yog sib npaug rau 10% DMSO, ces sib tov maj mam.

Yog tias yuav tsum tau ua kom tsis muaj menyuam, 0.22 µm filtration (PVDF / nylon) tom qab tag nrho dissolution.

Cia

Lyophilized: khw -20℃rau -80 degree, qhuav, tiv thaiv los ntawm lub teeb.

Reconstituted cov txheej txheem: 2–8 degree: 24–48 h; -20 degree: mus txog 1-3 lub hlis; -80 degree: mus txog 6-12 lub hlis (assay{10}}dependent).

Rau cov tshuaj dilute heev (<100 µg/mL), consider 0.1% BSA or 0.01% polysorbate-20 to minimize surface adsorption

Semaglutide & Inflamation Research

Thoob plaws hauv metabolic thiab hepatic chaw, semaglutide nyoos hmoov tau txuas ntxiv mus rau dampening qis - qib o dhau glycemic thiab qhov hnyav. Meta-Kev tshuaj xyuas thiab tshuaj xyuas piav qhia txog kev txo qis hauv cov neeg sib kho kom sib haum xeeb-CRP, IL-6 thiab TNF- -nrog rau kev txhim kho hauv cov teeb liab inflammatory, qhia txog qhov hnyav ncaj qha lossis ib nrab- ywj siab tiv thaiv. Cov teeb liab no ua raws li kev soj ntsuam hauv daim siab / kab mob metabolic qauv, qhov twg cov koom haum semaglutide nrog kev daws teeb meem - txuas proteomic hloov pauv thiab nqes -kev tswj hwm ntawm fibrosis- txoj hauv kev mob, muab ib qho kev sib txuas rau kev hloov pauv kev pheej hmoo plawv. Thaum heterogeneity hauv kev ntsuam xyuas thiab kev kho keeb kwm yav dhau tseem tseem nyob, tus qauv tag nrho txhawb kev tshawb fawb txuas ntxiv ntawm biomarker-guided designs kom meej meej causality thiab koob tshuaj- teb.

Ntau-Txoj Kev Nyuaj Siab- Kev Tswj Xyuas Kev Tshawb Fawb

Kev sib xyaw lossis "multi-target" los tiv thaiv- kev kho rog rog nrog semaglutide tsom rau kev sib koom ua ke GLP-1 receptor agonism nrog rau qhov thib ob, txoj hauv kev ntxiv, feem ntau yog qhov ntev - ua yeeb yam amylin analogues xws li cagrilintide. Thaum co-formulated (feem ntau hu ua CagriSema), ob tus neeg ua haujlwm ua haujlwm ntawm kev sib tshooj hauv nruab nrab satiety circuits thiab ua rau lub plab zom mov, ua kom lub zog sib sib zog nqus thiab ntau dua - txo qis dua li GLP-1 monotherapy. Theem 2/thaum ntxov 3 cov kev tshawb fawb tau tshaj tawm ntau dua ntawm cov neeg mob ua tiav cov txiaj ntsig kev noj qab haus huv uas muaj txiaj ntsig zoo (piv txwv li Ntau dua lossis sib npaug li 15%), nrog rau cov txiaj ntsig zoo hauv cov ntshav siab thiab cov cim inflammatory, qhia txog cov txiaj ntsig cardiometabolic. Parallel cov kev pab cuam uas koom ua ke GLP-1 thiab amylin kev ua haujlwm rau hauv ib qho molecule (xws li amycretin) taw qhia rau tiam tom ntej ntawm ntau cov tshuaj metabolic.

Lub raum -Kev Tiv Thaiv Kev Tshawb Fawb

Tam sim no Semaglutide tau qhia rau lub raum-cov txiaj ntsig tshwj xeeb hauv hom 2 mob ntshav qab zib mellitus nrog rau mob raum tsis zoo, feem ntau pom tseeb hauv kev sim FLOW, qhov twg ib zaug -kev kho mob txhua lub limtiam txiav cov ntsiab lus kawg ntawm ntau dua lossis sib npaug rau 50% eGFR poob, lub raum tsis ua haujlwm, lossis lub raum / plawv plawv tuag los ntawm kev ua raws li ntawm 24% ntau dua 24% 3.4 xya. Cov hlab plawv thiab tag nrho -ua rau kev tuag kuj muaj pes tsawg, uas zoo ib yam nrog cov txiaj ntsig ntawm kev mob plawv. Cov txiaj ntsig no tsis zoo li yuav piav qhia los ntawm kev txo cov piam thaj ib leeg; poob phaus, txo qis ntshav siab, thiab kev poob qis hauv albuminuria tej zaum yuav ua ke, thiab intrarenal GLP-1 signaling tseem yog ib qho plausible mechanism. Nyob rau sab nraum qab ntawm cov ntaub ntawv no, cov neeg tswj hwm hauv 2025 tau txuas ntxiv daim ntawv lo "txo qhov kev pheej hmoo ntawm cov kab mob hauv lub raum thiab cov hlab plawv tuag" hauv cov neeg no, muab cov semaglutide nrog rau SGLT2 inhibitors ntau dua li qab lawv.

Cim npe nrov: Tuam Tshoj semaglutide raw hmoov manufacturers, lwm tus neeg, Hoobkas